Windlas Biotech Limited has approved the grant of stock options and units to eligible employees under its employee benefit schemes. The Nomination and Remuneration Committee of the Board of Directors sanctioned the allotment on May 21, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company granted a total of 37,000 options and units across two distinct plans. The WBL Employee Stock Option Scheme 2023 (ESOS 2023) accounted for 15,750 options, while the Windlas Plan 2025 accounted for 21,250 units. Each option or unit, upon exercise, entitles the holder to one fully paid-up equity share with a face value of ₹5.

Details of the Grant

The schemes differ in their pricing structures and vesting schedules. The ESOS 2023 options are priced at a discount of up to 25% from the market price of the shares as on the date of grant. Conversely, the units under the Windlas Plan 2025 are granted at face value, specifically ₹5 per unit.

Scheme Breakdown

Vesting and Exercise Terms

Options granted under the ESOS 2023 will vest not earlier than one year and not later than four years from the grant date. The exercise period for these vested options is a maximum of four years commencing from the vesting date.

For the Windlas Plan 2025, the units vest in four equal instalments of 25% each. These instalments vest upon the expiry of 12, 24, 36, and 48 months respectively from the effective grant date. Vested units under this plan can be exercised within a period of four years from the date of vesting, subject to the conditions specified in the plan.

Windlas Biotech has informed stock exchanges of a temporary disruption in operations at certain of its manufacturing sites on May 18, 2026, following a statewide labour unrest situation in Uttarakhand. The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/CFD/PoD2/CIR/P/2026/14 dated January 30, 2026.

Labour Unrest Across Uttarakhand

The labour protest was triggered across various industrial areas in the state, including Dehradun and Haridwar, leading to work stoppages at multiple manufacturing plants across several industries. The statewide nature of the unrest affected operations at Windlas Biotech's manufacturing sites, which are located in the Mohabewala Industrial Area, Dehradun.

Operational Impact and Restoration

The following table summarises the key details of the incident as disclosed by the company:

Production was restored by the evening shift on the same day, and operations have since resumed across all sites. The company stated that it currently does not envisage any material impact on its operations, supply chain, or financial performance as a result of this disruption.

Administration and Monitoring

The local administration and relevant authorities are actively engaging in the region to facilitate an early restoration of normalcy. Windlas Biotech's management has stated that the situation is being closely monitored. The disclosure was signed by Ananta Narayan Panda, Company Secretary and Compliance Officer, on May 18, 2026.